Bertolt Kreft PhD

Bertolt Kreft has served as our Chief Scientific Officer since February 2020.  Bertolt is an expert in cancer drug discovery with 20 years of pharmaceutical industry experience and a broad background in oncology research covering target validation, biologics and small molecule lead discovery, as well as research supporting pre-IND, early and late-stage clinical development programs.  Prior to joining Bright Peak, Bertolt served as VP Immuno-Oncology at Bayer AG.  From 2009 to 2020, he was responsible for cancer drug discovery efforts at Bayer focused on Immuno-Oncology, antibody-drug conjugates (ADC), and biologics.  Bertolt entered pharmaceutical industry with Schering AG in 1999 where he held positions of increasing responsibility including group leader in target identification & validation.  Bertolt received a PhD in biochemistry from the Free University Berlin/Charité (Germany), followed by a postdoctoral fellowship at University of North Carolina, Chapel Hill.  He holds a diploma in biochemistry from the Free University Berlin.